Manager, SOX Compliance and Technical Accounting

Location: Menlo Park, CA / Princeton, NJ / Miami, FL ONSITE

About Summit:

Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence.

Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including:

Non-small Cell Lung Cancer (NSCLC)

• HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI.

• HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC.

• HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC.

Colorectal Cancer (CRC)

• HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy.

Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland.

Overview of Role:

The Manager, SOX Compliance and Technical Accounting will be responsible for Ongoing SOX compliance and be involved in complex accounting transactions including accruals, collaboration accounting, and other technical areas. This role will report to the Associate Director, SEC Reporting & Tech Accounting.

Role and Responsibilities:

• Lead the company’s SOX 404 implementation program (under COSO framework), including scoping, risk assessment, control design, testing, and remediation.
• Develop and maintain an inventory of key controls in a Risk and Control Matrix (RCM), which includes the mapping of controls to the relevant financial statement line items, control type (manual vs. IT), and frequency of the control (daily, weekly, etc.).
• Maintain comprehensive controls documentation, including narratives, flowcharts, and risk/control matrices.
• Partner with IT, FP&A, and Clinical teams to develop and monitor automated controls and system dependencies that are well-designed and documented. Serve as a trusted advisor on IT general controls for these groups.
• Liaise with internal and external auditors and coordinate SOX scoping, testing, and remediation of findings.
• Serve as a bridge between Finance/Accounting team and Internal and external auditors to coordinate audit timelines and scope.
• Serve as the central point of contact for all SOX audit requests from internal and external auditors and manage the process for timely completion of audit.
• Partner cross-functionally to develop and strengthen appropriate entity-level controls, business process (manual & automated) controls, incident reporting frameworks, and reporting structures expected of a public company.
• Evaluate and strengthen controls over system access, change management, and data integrity for all in-scope systems.